You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory or relapsed Follicular Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma, Refractory Follicular Lymphoma Trial (Tazverik (Tazemetostat))

Not yet recruiting
  • Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Tazverik (Tazemetostat)
  • (no location specified)
Oct 6, 2023

Follicular Lymphoma Trial in Shanghai (lenalidomide, rituximab, parsaclisib)

Not yet recruiting
  • Follicular Lymphoma
  • Shanghai, Shanghai, China
    Ruijin hospital, school of medicine, Shanghai jiao tong universi
May 10, 2023

Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)

Not yet recruiting
  • Follicular Lymphoma
  • Axicabtagene Ciloleucel
  • +5 more
  • (no location specified)
Sep 21, 2023

Obinutuzumab in Combination With Lenalidomide in Relapsed or

Recruiting
  • Follicular Lymphoma
    • Tianjin, China
      Institute of Hematology and Blood Diseases Hospital ,Chinese Aca
    Apr 27, 2023

    Relapsed/Refractory Follicular Lymphoma With EZH2 Trial in Shanghai (Tazemetostat)

    Not yet recruiting
    • Relapsed/Refractory Follicular Lymphoma With EZH2
    • Shanghai, Shanghai, China
      Shanghai Cancer Center
    Jul 20, 2022

    Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Boston (TAZEMETOSTAT, Zandelisib)

    Not yet recruiting
    • Relapsed Follicular Lymphoma
    • Refractory Follicular Lymphoma
    • Boston, Massachusetts
    • +1 more
    Oct 28, 2022

    Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

    Recruiting
    • Relapsed/Refractory Follicular Lymphoma
    • Marginal Zone Lymphoma (MZL)
    • Chiang Mai, Thailand
      Chiang Mai University
    Nov 20, 2023

    Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

    Active, not recruiting
    • Indolent Non-hodgkin Lymphoma
    • Shanghai, China
      Ruijin hospital, school of medicine, Shanghai jiao tong universi
    Oct 3, 2022

    Lymphoma Trial in Houston (Rituximab, Lenalidomide, Valemetostat)

    Not yet recruiting
    • Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 4, 2023

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

    Recruiting
    • Relapsed/Refractory Follicular Lymphoma
    • Marginal Zone Lymphoma
    • Westbury, New York
      Clinical Research Alliance, Inc.
    Nov 14, 2022

    Follicular Lymphoma (FL) Trial (biological, drug, other)

    Not yet recruiting
    • Follicular Lymphoma (FL)
    • Tisagenlecleucel
    • +4 more
    • (no location specified)
    May 24, 2023

    Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)

    Recruiting
    • Refractory Follicular Lymphoma
    • Relapsed Follicular Lymphoma
    • Washington, District of Columbia
    • +2 more
    Jul 6, 2022

    Relapsed/Refractory Follicular Lymphoma Trial in Nashville (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)

    Recruiting
    • Relapsed/Refractory Follicular Lymphoma
    • Axicabtagene Ciloleucel
    • +8 more
    • Denver, Colorado
    • +6 more
    Dec 2, 2022

    Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

    Recruiting
    • Follicular Lymphoma
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)

    Not yet recruiting
    • T Cell Lymphoma
    • Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
    • (no location specified)
    Mar 6, 2023

    Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

    Completed
    • Grade 3a Follicular Lymphoma
    • +9 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 31, 2023

    Follicular Lymphoma Trial in Miami (Loncastuximab tesirine, Rituximab)

    Recruiting
    • Follicular Lymphoma
    • Miami, Florida
      University of Miami
    Jul 11, 2022

    Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

    Recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • +6 more
    • Beijing, China
      Beijing Cancer Hospital
    Feb 6, 2023

    Adult Patients Who Initiate Systemic Treatment for Relapsed or

    Recruiting
    • Relapsed/Refractory Follicular Lymphoma
    • Non-Interventional
    • Graz, Austria
    • +8 more
    Sep 19, 2022

    Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • +5 more
    • (no location specified)
    Aug 4, 2023

    Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

    Not yet recruiting
    • Lymphoma, B-Cell
    • +7 more
    • Adaptive Bridging Radiation Therapy (ABRT)
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Aug 16, 2023

    Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)

    Not yet recruiting
    • Recurrent Follicular Lymphoma
    • Refractory Follicular Lymphoma
    • Duarte, California
      City of Hope Medical Center
    Jul 31, 2022

    Non Hodgkin Lymphoma, Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Ostrava-, Oslo (Betalutin)

    Completed
    • Non Hodgkin Lymphoma
    • +2 more
    • Ostrava-, Porubá, Czechia
    • +1 more
    Sep 30, 2022

    Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma Trial in Guangzhou (Orelabrutinib and Rituximab, Orelabrutinib)

    Recruiting
    • Follicular Lymphoma
    • Relapsed and Refractory Follicular Lymphoma
    • Guangzhou, Guangdong, China
    • +2 more
    Mar 23, 2022